Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms

Blood (2019) 134 (Supplement_1): 474.

https://doi.org/10.1182/blood-2019-127235

Published: 2019

Journal Articles

A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function

Julio C. Chavez, MD, Ariel F Grajales-Cruz, MD, Virginia Olivia Volpe, MD, Elyce P. Turba, MSN, RN, Lisa Nodzon, PhD ARNP, AOCNP, Eva Sahakian, PhD, Nicole Rozario, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 5483.

https://doi.org/10.1182/blood-2019-132211

Published: 2019

Journal Articles

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

Hannah Asghari, MD BS, Chetasi Talati, MD, Alexandra Achille, John J. Powers, BS, Eva Sahakian, PhD, Onyee Chan, MD, Dawne N Shelton, PhD, Leidy Isenalumhe, MD, Lisa Nodzon, PhD ARNP, AOCNP, Kendra L. Sweet, MD, Javier Pinilla Ibarz, MD PhD

Blood (2019) 134 (Supplement_1): 3382.

https://doi.org/10.1182/blood-2019-131207

Published: 2019

Journal Articles

Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival

AGM Mostofa, PhD, Allison Distler, Mark B. Meads, PhD, Eva Sahakian, PhD, John J. Powers, BS, Tuan Nguyen, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD, Eduardo Sotomayor, MD, Kenneth H. Shain, MD PhD, Jason B. Brayer, PhD MD

Blood (2018) 132 (Supplement 1): 3223.

https://doi.org/10.1182/blood-2018-99-119119

Published: 2018

Journal Articles

Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment

Jie Chen, PhD, Fengdong Cheng, MD, Michael Wang, Bachelor of Science, Eva Sahakian, PhD, John J. Powers, BS, Javier Pinilla Ibarz, MD, Mitchell R. Smith, MDPhD, Eduardo Sotomayor, MD

Blood (2018) 132 (Supplement 1): 1105.

https://doi.org/10.1182/blood-2018-99-117007

Published: 2018

Journal Articles

Differential Regulation of T Cells By PI3K Delta Inhibitors in a CLL Murine Model

Kamira Maharaj, PhDCandidate, John J. Powers, BS, Alex Achille, BS, Mibel Pabon-Saldana, PhD, Renee Fonseca, BS, Susan Deng, BS, Hari P Miskin, MSc, Dave Maryanski, BS, Eva Sahakian, PhD, Javier Pinilla-Ibarz, MD PhD

Blood (2017) 130 (Supplement 1): 3009.

https://doi.org/10.1182/blood.V130.Suppl_1.3009.3009

Published: 2017

Journal Articles

HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma

Jason B. Brayer, PhDMD, Allison Distler, Mark B. Meads, PhD, Eva Sahakian, PhD, John J. Powers, BS, Tuan Nguyen, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Javier Pinilla-Ibarz, MD PhD, Eduardo Martin Sotomayor, MD, Ken H Shain, MD PhD

Blood (2017) 130 (Supplement 1): 1800.

https://doi.org/10.1182/blood.V130.Suppl_1.1800.1800

Published: 2017

Journal Articles

A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease

Kendra L. Sweet, MD, Lori Hazlehurst, PhD, Eva Sahakian, PhD, John J. Powers, B.S., Lisa Nodzon, PhD ANP, Fadi Kayali, MD, Kelly Hyland, Ashley Nelson, Javier Pinilla-Ibarz, MD PhD

Blood (2016) 128 (22): 1892.

https://doi.org/10.1182/blood.V128.22.1892.1892

Published: 2016

Journal Articles

Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model

Kamira Karen Maharaj, BS, John J. Powers, B.S., Susan Deng, BS, Alex Achille, BS, Mibel Pabon-Saldana, Renee Fonseca, Steven N Quayle, Simon S Jones, PhD, Eva Sahakian, PhD, Javier Pinilla-Ibarz, MD PhD

Blood (2016) 128 (22): 2035.

https://doi.org/10.1182/blood.V128.22.2035.2035

Published: 2016

Journal Articles

Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202

Kamira Karen Maharaj, BS, John J. Powers, B.S., Mibel Pabon-Saldana, Renee Fonseca, Alex Achille, BS, Susan Deng, BS, Hari P. Miskin, MS, Dave Maryanski, Eva Sahakian, PhD, Javier Pinilla-Ibarz, MD PhD

Blood (2016) 128 (22): 3236.

https://doi.org/10.1182/blood.V128.22.3236.3236

Published: 2016

Journal Articles

A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma

Jason B. Brayer, MDPhD, Eva Sahakian, PhD, John Powers, M.S., Mark B Meads, PhD, Susan Deng, Allison Distler, Melissa Alsina, MD, Taiga Nishihori, MD, Rachid Baz, MD, Alejandro Villagra, PhD, Javier Pinilla-Ibarz, MD PhD, Eduardo M. Sotomayor, MD, Kenneth H. Shain, MD PhD

Blood (2014) 124 (21): 4715.

https://doi.org/10.1182/blood.V124.21.4715.4715

Published: 2014

Journal Articles

Selective Inhibition of HDAC6 Decreases Viability of Cutaneous T-Cell Lymphoma and Improves Immune Recognition

Tessa Knox, MS, Maritza Lienlaf, MS, Patricio Perez-Villarroel, BS., Calvin Lee, MD, Eva Sahakian, PhD, John J. Powers, B.S., Fengdong Cheng, MD, Jorge Canales, MS, Danay Marante, MS, Ed Seto, PhD, Eduardo M. Sotomayor, MD, Alejandro Villagra, PhD, Pedro Horna, MD

Blood (2014) 124 (21): 5423.

https://doi.org/10.1182/blood.V124.21.5423.5423

Published: 2014

Journal Articles

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Fengdong Cheng, MD, Bing Xia, MD, Eva Sahakian, PhD, Tint Lwin, MD PhD, Hongwei Wang, MD, Limin Xing, MD, Bijal D. Shah, MD, Patricio PerezVillarroel, BS, Maritza LienlafMoreno, BS, Yizhuo Zhang, MD, Steven N Quayle, PhD, Simon S Jones, PhD, Javier Pinilla-Ibarz, MD PhD, Alejandro Villagra, PhD, Eduardo M. Sotomayor, MD, Jianguo Tao, MD PhD

Blood (2014) 124 (21): 5397.

https://doi.org/10.1182/blood.V124.21.5397.5397

Published: 2014

Journal Articles

Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL)

John J. Powers, B.S., Kamira K. Maharaj, B.S., Eva Sahakian, PhD, Limin Xing, PhD, Patricio PerezVillarroel, BS, Tessa Knox, MS, Steven Quayle, Simon S Jones, PhD, Alejandro Villagra, PhD, Eduardo M. Sotomayor, MD, Javier Pinilla-Ibarz, MD PhD

Blood (2014) 124 (21): 3311.

https://doi.org/10.1182/blood.V124.21.3311.3311

Published: 2014

Journal Articles

Histone Deacetylase 11 (HDAC11) As a Novel Transcriptional Regulator of C/EBP-β, in Immature Myeloid Cell to Myeloid Derived Suppressor Cell Transition

Jie Chen, MA, Eva Sahakian, PhD, John J. Powers, B.S., Maritza LienlafMoreno, BS, Limin Xing, PhD, Susan Deng, Allison Distler, Fengdong Cheng, MD, Alejandro Villagra, PhD, Pedro Horna, MD, Eduardo M. Sotomayor, MD, Javier Pinilla-Ibarz, MD PhD

Blood (2014) 124 (21): 225.

https://doi.org/10.1182/blood.V124.21.225.225

Published: 2014

NARROW

Selective Targeting of Histone Deacetylase 11 Disables Metabolism of Myeloproliferative Neoplasms

A Phase II Trial of Ibrutinib and PD-1 Blockade in Asymptomatic High Risk Chronic Lymphocytic Leukemia to Improve Immune Function

Conventional Real Time Quantitative Polymerase Chain Reaction Method Yields Similar Level of Sensitivity to Digital Droplet Polymerase Chain Reaction for Detection of BCR-ABL p210 Transcripts in Patients with Chronic Phase Chronic Myeloid Leukemia

Functional Analysis of HDAC11 in Plasma Cell Development and Multiple Myeloma Survival

Loss of HDAC11 Promotes Myeloid-Derived Suppressor Cells Inhibition of T Cell Function in a Murine Lymphoma Microenvironment

Differential Regulation of T Cells By PI3K Delta Inhibitors in a CLL Murine Model

HDAC11 Is a Candidate Therapeutic Target in Multiple Myeloma

A Phase I Study of Ruxolitinib Plus Nilotinib in Chronic Phase CML Patients with Molecular Evidence of Disease

Combinatorial Effect of HDAC6i and Ibrutinib Therapy in CLL Murine Model

Modulation of T Cell Compartment in a Preclinical CLL Murine Model By a Selective PI3K Delta Inhibitor, TGR-1202

A Novel Role for Histone Deacetylase 11 (HDAC11) in B Cell Lymphopoiesis and Plasma Cell Survival in Multiple Myeloma

Selective Inhibition of HDAC6 Decreases Viability of Cutaneous T-Cell Lymphoma and Improves Immune Recognition

Selective Inhibition of Histone Deacetylase 6 (HDAC6) and HDAC3 As a Novel Therapeutic Strategy in Mantle Cell Lymphoma (MCL)

Histone Deacetylase 6 (HDAC6) As a Regulator of Immune Check-Point Molecules in Chronic Lymphocytic Leukemia (CLL)

Histone Deacetylase 11 (HDAC11) As a Novel Transcriptional Regulator of C/EBP-β, in Immature Myeloid Cell to Myeloid Derived Suppressor Cell Transition

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only